SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF
Provided are therapeutic compositions containing ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
1 . - 10 . (canceled)
11 . A therapeutic composition comprising an effective amount of a bacterial combination comprising a first purified bacterial population and a second purified bacterial population, the first purified bacterial population comprising a first 16S rDNA sequence at least 95% identical to a first member of a binary pair selected from Table 3 and the second purified bacterial population comprising a second16S rDNA sequence at least 95% identical to a second member of the binary pair selected from Table 3, wherein the binary pair can synergistically inhibit Clostridium difficile growth in a CivSim assay and wherein the therapeutic composition is formulated for oral delivery.
12 . The therapeutic composition of claim 11 , wherein the binary pair can synergistically inhibit Clostridium difficile growth in a CivSim assay with a confidence interval of >99% (++++).
13 . The therapeutic composition of claim 11 , wherein the first member has a 16S rDNA at least 95% identical to SEQ ID NO:705 or SEQ ID NO:1896.
14 . The therapeutic composition of claim 11 , wherein the first member is a Dorea longicatena.
15 . The therapeutic composition of claim 11 , wherein the first 16S rDNA sequence is at least 97% identical to the first member of a binary pair selected from Table 3 and the second 16S rDNA sequence is at least 97% identical to the second member of the binary pair selected from Table 3.
16 . The therapeutic composition of claim 11 , wherein the first 16S rDNA sequence is 100% identical to the first member of a binary pair selected from Table 3 and the second 16S rDNA sequence is 100% identical to the second member of the binary pair selected from Table 3.
17 . The therapeutic composition of claim 11 , wherein at least one of the 16S rDNA sequences is a 16S rDNA V4 sequence.
18 . The therapeutic composition of claim 11 , wherein at least one of the first purified bacterial population and the second purified bacterial population is capable of functionally populating a gastrointestinal tract of a human subject.
19 . The therapeutic composition of claim 18 , wherein the functional populating of the gastrointestinal tract comprises reducing the number of one or more types of pathogenic bacteria in the gastrointestinal tract, and/or increasing the number of one or more non-pathogenic bacteria in the gastrointestinal tract.
20 . The therapeutic composition of claim 11 , wherein the first purified bacterial population or the second purified bacterial population is a spore-forming bacteria.
21 . The therapeutic composition of claim 11 , wherein the first purified bacterial population and the second purified bacterial population are both spore-forming bacteria.
22 . The therapeutic composition of claim 11 , wherein the first purified bacterial population or the second purified bacterial population is in a spore form.
23 . The therapeutic composition of claim 11 , wherein the first purified bacterial population and the second purified bacterial population are in a spore form.
24 . The therapeutic composition of claim 11 , wherein the bacterial combination consists of the first and second bacterial populations.
25 . The therapeutic composition of claim 11 , wherein the effective amount is 10̂8 or 10̂9 or 10̂10 total viable CFU of the bacterial combination.
26 . The therapeutic composition of claim 11 , further comprising an effective amount of an anti-bacterial agent, an anti-fungal agent, an anti-viral agent or an anti-parasitic agent.
27 . The therapeutic composition of claim 11 , formulated in a capsule.
28 . The therapeutic composition of claim 27 , encapsulated in an enteric coating.
29 . A method of treating or preventing recurrence of Clostridium difficile infection in a gastrointestinal tract in a mammal, the method comprising administering the therapeutic composition of claim 11 to the mammal.
30 . The method of claim 29 , wherein the mammal is a human.